logo

FDA Calendar

Share SHARE
PDUFA dates and FDA Panel Review dates are very important because they are make or break events for biostocks when the decisions are announced. Also, usually biostocks experience a run-up going into the scheduled decision/review dates. So having prior knowledge of the catalysts goes a long way toward maximizing profit or minimizing loss while trading volatile biotech stocks.

Listed below are large cap, mid cap and small cap stocks with pending regulatory catalysts.

Get in-depth analysis and insight on investing in the high-stakes biotech and pharma sectors. Check out our
premium biotech research product and our biotech home page.
Company Name
Ticker
Drug
Event
Date
Outcome
Details
Anacor Pharmaceuticals, Inc.
Crisaborole topical ointment, 2% (NDA)
FDA decision on Crisaborole for treatment of mild-to-moderate atopic dermatitis in children and adults.
01/07/2017
Vericel Corporation
MACI (BLA)
FDA decision on MACI for the treatment of symptomatic cartilage defects of the knee in adult patients
01/03/2017
Roche Holding AG
OCREVUS (BLA)
FDA decision on OCREVUS for the treatment of relapsing multiple sclerosis and primary progressive multiple sclerosis
12/28/2016
Advanced Accelerator Applications S.A.
Lutathera (NDA)
FDA decision on Lutathera for the treatment of gastro entero pancreatic neuroendocrine tumors
12/28/2016
Cempra, Inc.
Solithera oral (NDA)
FDA decision on Solithera as a treatment for community-acquired bacterial pneumonia
12/28/2016
Cempra, Inc.
Solithera IV (NDA)
FDA decision on Solithera as a treatment for community-acquired bacterial pneumonia
12/27/2016
Dynavax Technologies Corp
HEPLISAV-B (BLA)
FDA decision on HEPLISAV-B for immunization of adults against hepatitis B infection
12/15/2016
Spectrum Pharmaceuticals Inc
EOquin (NDA)
FDA decision on EOquin for the treatment of non-invasive bladder cancer
12/11/2016
Lexicon Pharmaceuticals Inc.
Telotristat Etiprate (NDA)
FDA decision on Telotristat Etiprate for the treatment of carcinoid syndrome
11/30/2016
Valeant Pharmaceuticals International
VRX, VRX.TO
Brodalumab (BLA)
FDA decision on Brodalumab for treatment of patients with moderate-to-severe plaque psoriasis.
11/16/2016
Gilead Sciences Inc.
Tenofovir Alafenamide (TAF) (NDA)
FDA decision on TAF for treatment of chronic hepatitis B
11/12/2016
Bristol-Myers Squibb Co.
Opdivo (sBLA)
FDA decision on Opdivo for previously treated recurrent or metastatic squamous cell carcinoma of the head and neck
11/11/2016
Amgen Inc.
Enbrel (sBLA)
FDA decision on Enbrel for the expanded use to treat pediatric patients with chronic severe plaque psoriasis.
11/05/2016
Regeneron Pharmaceuticals
Sarilumab (BLA)
FDA decision on Sarilumab for the treatment of patients with rheumatoid arthritis
10/30/2016
Sanofi
Sarilumab (BLA)
FDA decision on Sarilumab for the treatment of patients with rheumatoid arthritis.
10/30/2016
Pharma-072616.jpg Shares of GenVec Inc. (GNVC) rose over 50% in extended trading on Monday after being notified that the FDA has lifted the clinical hold on the Phase 1/2 clinical trial of CGF166 in patients with severe to profound hearing loss.
Pharma-072516.jpg Tobira Therapeutics Inc. (TBRA) is all set to hold a teleconference and webcast at 8:30 a.m. Eastern Time today (July 25) to discuss phase IIb results for Cenicriviroc in patients with non-alcoholic steatohepatitis and liver fibrosis. Will Cenicriviroc make a mark? We will have to wait for the results.
Pharma-072016.jpg Shares of Puma Biotechnology Inc. (PBYI) were up over 20% in extended trading on Thursday, following encouraging interim 5-year invasive disease free survival results from the company's phase III trial of PB272 (Neratinib) in extended adjuvant HER2-positive early stage breast cancer.
More
The number of drug resistant cases of gonorrhea have increased in the U.S. in recent years, according to a new study from researchers at the Centers for Disease Control and Prevention. The agency released an official statement earlier this week noting that "the future of current treatment options may be in jeopardy."
Use of the wildly popular new gaming app Pokemon Go may help people with mental illness feel better, according to a new study from researchers at Media Psychology Research Center in Newport Beach, California. According to the Center's report, users that are otherwise largely sedentary and bound to the indoors may be getting more exercise and social interaction than normal because of the game.
Parents should be wary of their children's exposure to violence in the media, according to a new study from researchers at the American Academy of Pediatrics (AAP). According to the new statement, there is a clear and traceable connection between the amount of violence kids take in from the media and increased aggressive behavior. "With children, actual physical violence is, thankfully, rare."
More
comments powered by Disqus